|
Author
|
Treatment regimen
|
No. of patients
|
Gastrointestinal toxicity (≥ Grade 3)
|
Hematologic toxicity (≥ Grade 3)
|
Local failure rate
|
Median PFS (months)
|
Median OS (months)
|
|---|
|
Cohen et al.[7]
|
RT 59.4 Gy/5-FU+mitomycin
|
55
|
13%
|
20%
|
NA
|
5.1
|
8.4
|
|
Ishii et al.[8]
|
RT 50.4 Gy/5-FU
|
20
|
15%
|
0%
|
35%
|
4.9
|
10.3
|
|
Kornek et al.[9]
|
RT 55 Gy/5-FU+cisplatin
|
38
|
18%
|
18%
|
NA
|
10
|
14
|
|
Boz et al.[10]
|
RT 59.4 Gy/5-FU
|
42
|
4%
|
16%
|
51%
|
6.2
|
9.1
|
|
Magnino et al.[12]
|
RT 45 Gy/GEM
|
23
|
30%
|
39%
|
22%
|
NA
|
12
|
|
Blackstock et al.[13]
|
RT 50.4 Gy/GEM
|
39
|
41%
|
69%
|
15%
|
NA
|
7.9
|
|
Okusaka et al.[14]
|
RT 50.4 Gy/GEM
|
38
|
33%
|
52%
|
6%
|
4.4
|
9.5
|
|
Li et al.[15]
|
RT 50.4-61.2 Gy/GEM
|
18
|
28%
|
28%
|
34%
|
7.1
|
14.5
|
|
Murphy et al.[16]
|
*RT 36 Gy/GEM
|
74
|
11%
|
24%
|
26%
|
NA
|
11.2
|
|
This study
|
*RT 50 Gy/5-FU
|
10
|
0%
|
17%
|
8%
|
7.6
|
12.1
|
- Abbreviations: PFS = progression-free survival; OS = overall survival; RT = radiotherapy; 5-FU = 5-fluorouracil; GEM = gemcitabine; NA = not available.
- * Hypofractionated CCRT.
